Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT06205628 Recruiting - Hypertension Clinical Trials

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

Start date: March 21, 2024
Phase: Phase 1
Study type: Interventional

The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in patients with hypertension.

NCT ID: NCT06184269 Completed - Clinical trials for Essential Hypertension

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"

Start date: December 23, 2023
Phase: Phase 1
Study type: Interventional

The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1017-1" and co-administration of "BR1017-1A" and "BR1017-1B" in healthy volunteers

NCT ID: NCT06174766 Not yet recruiting - Hypertension Clinical Trials

A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients

Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate the Efficacy and Safety of HGP2102 in patients with Essential Hypertension

NCT ID: NCT06165250 Recruiting - Clinical trials for Essential Hypertension

A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C

Start date: April 17, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this clinical trial is to evaluate the efficacy and safety of co-administrated BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia

NCT ID: NCT06141200 Not yet recruiting - Clinical trials for Essential Hypertension

NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial

Start date: March 2024
Phase: Phase 3
Study type: Interventional

In this Phase III clinical trial, researchers evaluate the efficacy and safety of NW Roselle®, a powdered medicinal product developed by Natural Wellness. NW Roselle combines extracts from Hibiscus Sabdariffa (HS) flowers and Olea europaea (OE) leaves. The trial aims to gather evidence on the efficacy and safety of NW Roselle as a potential treatment option for Grade 1 essential hypertension.

NCT ID: NCT06130124 Recruiting - Clinical trials for Essential Hypertension

S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement

Start date: February 22, 2023
Phase:
Study type: Observational

Evaluate the ratio(%) of patients whose blood pressure measured at 6 months from the baseline was confirmed to be within the target blood pressure range according to the 2022 hypertension treatment guidelines for essential hypertension patients who received the study drug.

NCT ID: NCT06121518 Completed - Clinical trials for Essential Hypertension

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy

Start date: July 31, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy in Essential Hypertension Patients

NCT ID: NCT06116357 Not yet recruiting - Clinical trials for Primary Hypertension

The Safety and Efficacy of Carotid Body Modulation Therapy in Hypertensive Patients by External Ultrasonic Micro-bubble

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

The investigators intend to find a noninvasive method for CB modulation therapy and find a simple and convenient indicator for assessing CB activity. This study was designed to evaluate the safety and efficacy of carotid body modulation therapy in hypertensive patients by external ultrasonic micro-bubble and also identify the association between CB volume and CB activity.

NCT ID: NCT06093932 Not yet recruiting - Clinical trials for Hypertension,Essential

Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial

ESCIHP
Start date: December 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is: 1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension. 2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension. 3. To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.

NCT ID: NCT06091176 Not yet recruiting - Clinical trials for Essential Hypertension

Assessment of Efficacy and Safety of Amicomed®, for the Management of Essential Hypertension

Start date: November 1, 2024
Phase: N/A
Study type: Interventional

This is a multicenter, randomized, single-blind, parallel-group study to evaluate the efficacy and safety of Amicomed® compared with Usual Care (UC) over a 24-week treatment period in subjects with essential hypertension (mean, home based systolic blood pressure (SBP) ≥ 140 and/or diastolic blood pressure DBP ≥ 90 mm Hg on Day 1).